Retrospective studies of HER2-positive BC patients who have received NACT plus neoadjuvant anti-HER2 therapy have reported a higher rate of pCR in IHC 3+ compared to IHC 2+/HER2 amplified tumours [9]. This evidence concerns the gene ERBB2 and breast cancer.